ArticleNature2025
Cancer cells impair monocyte-mediated T cell stimulation to evade immunity.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers.
0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed.
- KAT6A inhibitor-loaded and anti-PD-L1-coated manganese metal-organic framework nanoplatform for enhanced colorectal cancer immunotherapy via cGAS-STING activation.International journal of pharmaceutics: X · 2026Article
- Monocyte Galectin-9 is associated with CD8⁺ T-cell dysfunction and early relapse after haploidentical hematopoietic stem cell transplantation.Biomarker research · 2026Article
- Chronic type II interferon promotes tumor growth through mitochondrial RNA-induced type I interferon and prostaglandin synthesis.Science (New York, N.Y.) · 2026Article
- CD1d remodels the tumor-infiltrating myeloid populations controlling antitumor immunity.The Journal of experimental medicine · 2026Article
- Pathophysiological roles of monocytes and macrophages in cancer.Nature reviews. Immunology · 2026Review
- Lipid metabolic reprogramming of tumor-associated macrophages drives resistance to immune checkpoint blockade in lung cancer: a narrative review of mechanisms and therapeutic strategies.Translational lung cancer research · 2026Review
- Uncoupling Type I Interferon Benefits From Inflammatory Toxicity: Transformer-Prioritized Precision Agonists for Potent and Safer Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A Molecular Trimming Strategy for Hypoxia-Tolerant Photosensitizers With Enhanced cGAS-STING Activation.Angewandte Chemie (International ed. in English) · 2026Article
- TIM3-targeted delivery of venetoclax overcomes drug resistance and reinvigorates NK cell activity in acute myeloid leukemia.Nature cancer · 2026Article
- Loss of NCCRP1 overcomes immune evasion in lung adenocarcinoma.Journal for immunotherapy of cancer · 2026Article
- Redirecting Monocyte Differentiation With Engineered Extracellular Vesicles for Glioma Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Chronic inflammation-responsive hydrogel restores myeloid-T cell crosstalk to reinvigorate antitumor immunity against metastatic colorectal cancer.Bioactive materials · 2026Article
- Regulation of immune checkpoint molecules in cancer immune evasion and therapy.Nature reviews. Cancer · 2026Review
- PANoptosis and Immune Remodeling in the Tumor Microenvironment.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Dendritic cell redundancy enables priming of anti-tumor CD4Cancer cell · 2026Article
- The lethal symbiont: exploring the pathophysiology of cancer.Physiological reviews · 2026Review
- Autonomous and Communicative Microcapsule Systems for Life-Like Homeostatic pH Regulation.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- DC-intrinsic SHP1 restrains central memory CD8⁺ T cell formation via the TCF-1/Wnt/β-Catenin axis.Medical oncology (Northwood, London, England) · 2026Article
- Targeting DGAT1 reprograms lipid landscape and restores CD8⁺ T cell immunity in pancreatic cancer.Nature communications · 2026Article
- Single-cell transcriptomics identifies key immune-suppressive cells and their driver genes in the bladder cancer microenvironment with prognostic implications.Molecular genetics and genomics : MGG · 2026Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Anais Elewaut *Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.ORCID 0009-0009-4064-7320
Guillem Estivill *Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.ORCID 0000-0002-8088-3098
Felix BayerlInstitute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.ORCID 0000-0002-4737-1808
Leticia CastillonTranslational Cancer Medicine Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Maria NovatchkovaResearch Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.
Elisabeth PottendorferResearch Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.
Lisa Hoffmann-HaasResearch Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.
Martin SchönleinResearch Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.ORCID 0000-0002-1010-0975
Trung Viet NguyenResearch Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.ORCID 0009-0000-1574-9610
Martin LaussLund University Cancer Center, Division of Oncology, Lund University, Lund, Sweden.
Francesco AndreattaResearch Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.ORCID 0000-0003-2749-9115
Milica VulinResearch Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.ORCID 0000-0002-7686-5102
Izabela KreciochResearch Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.
Jonas BayerlResearch Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.ORCID 0000-0001-6270-2823
Anna-Marie PeddeInstitute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.
Naomi FabreResearch Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.
Felix HolsteinResearch Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.ORCID 0000-0002-3729-9857
Shona M CroninResearch Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.
Sarah RieserResearch Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.
Denarda Dangaj LanitiLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.ORCID 0000-0002-5659-6427
David BarrasLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.ORCID 0000-0001-8985-4704
George CoukosLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.ORCID 0000-0001-8813-7367
Camelia QuekMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-1244-961X
Xinyu BaiMelanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Miquel Muñoz I OrdoñoResearch Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.ORCID 0009-0003-4391-6393
Thomas WiesnerDepartment of Dermatology, Medical University of Vienna, Vienna, Austria.
Johannes ZuberResearch Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.ORCID 0000-0001-8810-6835
Göran JönssonLund University Cancer Center, Division of Oncology, Lund University, Lund, Sweden.ORCID 0000-0001-6865-0147
Jan P BöttcherInstitute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.ORCID 0000-0002-8163-8107
Sakari VanharantaTranslational Cancer Medicine Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0001-5619-7963
Anna C ObenaufResearch Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria. anna.obenauf@imp.ac.at.ORCID 0000-0002-9556-5914
Funding
European Research Council 759590
Abstract
The tumour microenvironment is programmed by cancer cells and substantially influences anti-tumour immune responses
Indexed as
CD8-Positive T-LymphocytesLymphocyte ActivationMonocytesNeoplasmsT-LymphocytesTumor EscapeAnimalsCell Line, TumorDendritic CellsDinoprostoneFemaleHumansInterferon Type IMAP Kinase Signaling SystemMiceMice, Inbred C57BLDinoprostoneInterferon Type I
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.